BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+4.36%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.24B
AUM Growth
+$7.24B
(+2.4%)
Cap. Flow
+$197M
Cap. Flow
% of AUM
2.72%
Top 10 Holdings %
Top 10 Hldgs %
34.84%
Holding
226
New
18
Increased
74
Reduced
41
Closed
9
Top Buys
| 1 |
Relay Therapeutics
RLAY
|
$55.4M |
| 2 |
Exact Sciences
EXAS
|
$31M |
| 3 |
Ionis Pharmaceuticals
IONS
|
$22.1M |
| 4 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$20.8M |
| 5 |
MTEM
Molecular Templates, Inc.
MTEM
|
$16.9M |
Top Sells
| 1 |
Pacific Biosciences
PACB
|
$44M |
| 2 |
Halozyme
HALO
|
$33.2M |
| 3 |
Evolent Health
EVH
|
$21.8M |
| 4 |
AKCA
Akcea Therapeutics, Inc. Common Stock
AKCA
|
$20.4M |
| 5 |
Medtronic
MDT
|
$15.2M |
Sector Composition
| 1 | Healthcare | 95.98% |
| 2 | Industrials | 0.6% |
| 3 | Technology | 0.53% |
| 4 | Communication Services | 0.41% |
| 5 | Financials | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
QTNT
126
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $4.71M | 0.07% |
917,074
+317,920
| +53% | +$1.63M |
|
127
Inogen
INGN
$216M
| $4.32M | 0.06% |
148,912
| – | – |
|
128
GoHealth
GOCO
$81.7M
| $4.1M | 0.06% |
+314,672
| New | +$4.1M |
|
129
Outset Medical
OM
$247M
| $4M | 0.06% |
+79,921
| New | +$4M |
|
|
NUVA
130
DELISTED
NuVasive, Inc.
NUVA
| $3.99M | 0.06% |
82,100
+15,600
| +23% | +$758K |
|
|
BNR
131
Burning Rock Biotech
BNR
$93.6M
| $3.68M | 0.05% |
146,761
+101,761
| +226% | +$2.55M |
|
132
BioNTech
BNTX
$24B
| $3.43M | 0.05% |
49,500
-500
| -1% | -$34.6K |
|
133
Ultragenyx Pharmaceutical
RARE
$2.89B
| $3.37M | 0.05% |
41,000
+17,000
| +71% | +$1.4M |
|
134
AbbVie
ABBV
$372B
| $3.24M | 0.04% |
37,000
| – | – |
|
|
IMAB
135
I-MAB
IMAB
$340M
| $3.06M | 0.04% |
+65,000
| New | +$3.06M |
|
|
MRTX
136
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $2.96M | 0.04% |
17,800
| – | – |
|
137
Sanofi
SNY
$121B
| $2.86M | 0.04% |
57,000
| – | – |
|
138
Sarepta Therapeutics
SRPT
$1.78B
| $2.85M | 0.04% |
20,300
| – | – |
|
139
Pfizer
PFE
$141B
| $2.71M | 0.04% |
+73,900
| New | +$2.71M |
|
140
Biogen
BIIB
$19.4B
| $2.44M | 0.03% |
+8,600
| New | +$2.44M |
|
141
Ascendis Pharma
ASND
$11.8B
| $2.39M | 0.03% |
15,500
+2,200
| +17% | +$340K |
|
142
CureVac
CVAC
$1.21B
| $2.35M | 0.03% |
+50,500
| New | +$2.35M |
|
143
FibroGen
FGEN
$47.8M
| $2.18M | 0.03% |
+53,000
| New | +$2.18M |
|
|
GTH
144
DELISTED
Genetron Holdings Limited ADS
GTH
| $1.92M | 0.03% |
160,410
+60,410
| +60% | +$721K |
|
145
Acadia Pharmaceuticals
ACAD
$4.38B
| $1.85M | 0.03% |
44,900
| – | – |
|
|
BMY.RT
146
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $1.8M | 0.02% |
800,000
| – | – |
|
|
BHVN
147
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $1.59M | 0.02% |
+24,500
| New | +$1.59M |
|
|
CLLS
148
Cellectis
CLLS
$258M
| $1.55M | 0.02% |
83,500
| – | – |
|
149
Kura Oncology
KURA
$686M
| $1.47M | 0.02% |
+48,000
| New | +$1.47M |
|
150
uniQure
QURE
$896M
| $1.27M | 0.02% |
34,500
| – | – |
|